SAFE Identity and its predecessor SAFE-BioPharma have worked to make identity, digital signatures, authentication and encryption better and more secure for healthcare organizations. Our relying parties and partners are our priority, and the assurance SAFE technology, standards and policies have brought to the industry have already made a major impact on several of them. The case studies below are a testament to our SAFE-BioPharma legacy and show how we have become the industry standard for digital trust.
Signing and witnessing has long been a crucial part of drug research and converting this process to an electronic lab notebook has been an industry dream for many years to reduce the burden and documentation time for chemists. Pfizer achieved this dream when it successfully introduced to its Global Research and Development organization electronic notebooks signed with SAFE-BioPharma digital signatures. Pfizer’s digitally signed Chemistry electronic Notebooks (CeN) have more than 2200 users within Pfizer and average more than 1000 signatures per day.
In a move to comply with FDA regulations, advance to electronic processes, reduce paper-based costs and manage risk associated with electronic B2B transactions, AstraZeneca successfully used the SAFE-BioPharma standard to sign submissions made through the FDA’s Electronic Submissions Gateway. This is a milestone event that demonstrates to other companies one significant way the SAFE-BioPharma standard can accelerate progress toward the shared goal of greater efficiency and less paper. In recognition of this pioneering achievement, AstraZeneca received BIO-IT World Magazine’s 2008 Best Practices Grand Prize.
Using SAFE BioPharma interoperable digital identities, digital signatures and cloud computing, government and industry cancer researchers were able to accelerate initiation of a clinical trial while lowering its costs. The use of these digital identities eliminated use of paper copies and allowed signed documents to be exchanged rapidly and securely on-line for business processes initiated by the NCI/CTEP’s Protocol and Information Office (PIO). The ongoing study involves researchers at the National Cancer Institute, Bristol-Myers Squibb, and Sanofi.
Implementation of SAFE Digital Signatures at AstraZeneca (DIA)
Adobe 8 Manual Configuration Instructions
Arcot Universal Client SAFE-Compliant Digital Signatures (DIA)
Procter & Gamble (DIA)
SAFE-BioPharma Cooperative Model for Technology Enablement
SAFE Digital Signatures in PDF
SAFE Digital Identity and Digital Signature Standard (DIA)
SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care
SAFE Digital Identity and Signature Standard - HIPAA Summit
Realizing the National Health IT Strategy
SAFE-BioPharma Association’s Comments on 21 CFR Parts 1300, 1304, et al.
SAFE Testimony: HIT Policy Committee: NHIN Workgroup Planning Document
Adobe Solutions Brief
Adobe White Paper
The integrity of digital credentials varies widely from one provider to the next. Figuring out who to trust, why to trust them and how their security aligns with your needs can be a challenge. This makes trust hard.
The SAFE Identity Trust Framework, carefully cultivated over 15 years, can make trust much easier. The Trust Framework defines the policies and standards necessary to use secure and interoperable digital credentials that meet your needs. Issuers certified by SAFE are compliant with these policies and standards, ensuring this same security and interoperability across the ecosystem – and making trust a lot simpler for you.
Are you ready to consider your next steps ?
Rely on SAFE
1629 K Street Northwest #300
Washington, DC 20006
Admin@DirectTrust.org